Business
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer
CARLSBAD, Calif., November 20, 2025--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors w
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/e68fb6cf12afffa9fc4adb89b1568097"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vrdszE7VBmwGKXRdTQN6fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e68fb6cf12afffa9fc4adb89b1568097","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ipy5.BfYyR3C2lEbt09j2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e68fb6cf12afffa9fc4adb89b1568097","width":1200,"height":257}},"lazy":false},{"type":"text","content":"Test will serve as a companion diagnostic for Bayer’s HYRNUO™ (sevabertinib) to identify patients with NSCLC eligible for HER2-targeted therapy","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"CARLSBAD, Calif., November 20, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors with certain HER2/ERBB2 tyrosine kinase domain (TKD) activating mutations, helping determine which patients may benefit from HYRNUO™ therapy.","length":657,"tagName":"p"},{"type":"text","content":"The FDA also approved HYRNUO™ on November 19 for the treatment of adult patients with locally advanced or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations. The contemporaneous approval of Bayer’s therapy and Thermo Fisher’s companion diagnostic helps close access gaps, ensuring labs have access to essential companion testing as soon as the drug is available.","length":381,"tagName":"p"},{"type":"text","content":"Lung cancer remains the leading cause of cancer death worldwide, with NSCLC representing approximately 87 percent of all lung cancer cases.1 For patients with NSCLC presenting with HER2 mutations, this approval represents an opportunity to provide more targeted tr...